Chiasma, Inc. (Chiasma) is a biopharmaceutical company. The Company is focused on improving the lives of patients suffering from orphan diseases by developing and commercializing oral forms of therapies that are available by injection. Using the Company's Transient Permeability Enhancer (TPE), technology platform, it develops oral therapies associated with existing injectable therapies. It has completed a multinational Phase III clinical trial of its advanced Transient Permeability Enhancer platform-based product candidate, oral octreotide, for the treatment of acromegaly. The Company, through its TPE platform, has developed a pipeline of oral product candidates. It offers product, oral octreotide for various indications, such as Acromegaly-U.S., which has completed Phase III clinical trial; Acromegaly-E.U., which is in Phase III, and Neuroendocrine Tumor (NET) and New indication (orphan). The Company's wholly owned subsidiary is Chiasma (Israel) Ltd.